Edition:
India

Axovant Gene Therapies Ltd (AXGT.OQ)

AXGT.OQ on NASDAQ Stock Exchange Global Select Market

4.72USD
1:30am IST
Change (% chg)

$0.44 (+10.28%)
Prev Close
$4.28
Open
$4.27
Day's High
$4.83
Day's Low
$4.15
Volume
436,601
Avg. Vol
92,617
52-wk High
$7.21
52-wk Low
$1.42

Select another date:

Wed, Jun 10 2020

BRIEF-Axovant Gene Therapies Reports Q4 Loss Per Share Of $0.54

* AXOVANT ANNOUNCES YEAR-END FINANCIAL RESULTS AND EXPECTED KEY CLINICAL MILESTONES IN Q4 2020

BRIEF-Axovant Completes Enrollment Of Low-Dose Cohort In Phase 1/2 Study Of AXO-AAV-GM1, Expands Study

* AXOVANT COMPLETES ENROLLMENT OF LOW-DOSE COHORT IN PHASE 1/2 STUDY OF AXO-AAV-GM1 AND EXPANDS STUDY TO INCLUDE TYPE I (INFANTILE ONSET) PATIENTS WITH GM1 GANGLIOSIDOSIS

BRIEF-Axovant Enters Into Sales Agreement With SVB Leerink LLC

* AXOVANT GENE THERAPIES LTD - ENTERED INTO A SALES AGREEMENT WITH SVB LEERINK LLC, TO SELL COMMON SHARES HAVING OFFERING PRICE OF UP TO $25 MILLION Source text: (https://bit.ly/2yR4nsu) Further company coverage:

BRIEF-Axovant Announces Full Prepayment Of Outstanding Loan From Hercules Capital

* AXOVANT ANNOUNCES FULL PREPAYMENT OF OUTSTANDING LOAN FROM HERCULES CAPITAL

BRIEF-Axovant Gene Therapies Gave Notice To Voluntarily Prepay Amount Equal To $16 Mln, Under Loan And Security Agreement, Dated Feb 2, 2017

* AXOVANT GENE THERAPIES - ON APRIL 14, GAVE NOTICE TO VOLUNTARILY PREPAY AMOUNT EQUAL TO $16 MILLION, UNDER LOAN AND SECURITY AGREEMENT, DATED FEB 2, 2017

BRIEF-Axovant Announces Partnership With Invitae To Increase Access To Genetic Testing And Accelerate Diagnoses Of Gm1 And Gm2 Gangliosidosis

* AXOVANT ANNOUNCES PARTNERSHIP WITH INVITAE TO INCREASE ACCESS TO GENETIC TESTING AND ACCELERATE DIAGNOSES OF GM1 AND GM2 GANGLIOSIDOSIS

BRIEF-Axovant Provides Business, Operations Update During Covid-19 Pandemic

* AXOVANT PROVIDES BUSINESS AND OPERATIONS UPDATE DURING THE COVID-19 PANDEMIC

Select another date: